Angiogenesis in multiple myeloma.
Sezer
Orhan
O
Niemöller
Kathrin
K
Jakob
Christian
C
Heider
Ulrike
U
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism; D016228:Endothelial Growth Factors / Q000235:genetics / Q000494:pharmacology / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000502:physiology; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D015993:Life Tables; D008222:Lymphokines / Q000235:genetics / Q000494:pharmacology / Q000502:physiology; D008833:Microcirculation; D009101:Multiple Myeloma / Q000098:blood supply* / Q000188:drug therapy / Q000401:mortality; D009363:Neoplasm Proteins / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000209:etiology*; D011994:Recombinant Proteins / Q000494:pharmacology; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D015850:Interleukin-6; D008222:Lymphokines; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2